Xarelto Multidistrict Litigation

On December 12, 2014, the Judicial Panel on Multidistrict Litigation ordered the formation of MDL No. 2592 and transferred 21 federal court actions to the Eastern District of Louisiana for coordinated proceedings. The JPML Panel assigned Judge Eldon E. Fallon to oversee this MDL, entitled "In re: Xarelto (Rivaroxaban) Products Liability Litigation." Judge Fallon previously presided over the Vioxx litigation, which resulted in a settlement of $4.85 billion.

Xarelto (rivaroxaban) is an anticoagulant (blood thinning) drug, which has been marketed by its manufacturers Johnson & Johnson (a subsidiary of Janssen Pharmaceuticals) and Bayer as an alternative to Coumadin (warfarin). The drug is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism. It is often prescribed for patients undergoing hip and knee replacement surgery.

All blood thinners carry the risk of internal bleeding, but, unlike Coumadin/warfarin, internal bleeding with Xarelto cannot be reversed with any known treatments. Not surprisingly, there have been many reports of uncontrollable bleeding, hemorrhaging and death in the cases where Xarelto is used. Plaintiffs in this litigation, therefore, claim that Xarelto is defective because it is unreasonably dangerous to patients and is not a superior or safe alternative to Coumadin/warfarin. Plaintiffs further claim that the manufacturers withheld information from the public and the medical community, and have failed to adequately warn of the risk of nonreversible internal bleeding.

Our firm has extensive experience in complex cases involving mass actions or claims against drug manufacturers; and we have handled such claims, with success, in this same court and before the same judge involved in this case. Because of this track record, we are familiar with the processes by which this Xarelto case will be handled, and we are confident in our ability to achieve a just outcome for patients and their families.

If you or a loved one has suffered injury as a result of Xarelto, please contact our firm for an evaluation at 504-522-2304.